INTRODUCTION {#sec1-1}
============

Folate is an essential vitamin required for vital biochemical reactions in the human body, which includes one-carbon transfer reactions, and the formation of purines and pyrimidines for DNA and RNA synthesis.\[[@CIT1]\] Lack of folate has been undoubtedly linked to a number of disorders which includes carcinogenesis and anemia among others.\[[@CIT1][@CIT2]\] These in HIV-infected individuals could be a source of additional morbidity and increased mortality.

The role of folate in carcinogenesis has been well studied in colorectal cancers.\[[@CIT1]\] Epidemiologic studies have also associated folate deficiency with cancers of the lung, esophagus, stomach, brain, cervix, pancreas, and breast, and with leukemia.\[[@CIT3][@CIT4]\] It has been proposed that because folate is required for the synthesis of deoxythymidylate from deoxyuridylate,\[[@CIT5]\] the misincorporation of uracil during DNA synthesis could be a possible mechanism for carcinogenesis in folate deficiency. Similarly, it has also been proposed that alterations in DNA methylation due to folate deficiency could contribute to carcinogenesis by modulating gene expression.\[[@CIT6]\] Folate may affect immune cell proliferation and responsiveness due to its crucial role in nucleotide synthesis.\[[@CIT5]\]

Proliferation of various cell types have also been reported in folate deficiency.\[[@CIT7]--[@CIT9]\] Cells lacking folate have been shown to accumulate in the S phase due to nucleotide imbalance and slow DNA synthesis; it has also been reported that such cells also have increased uracil misincorporation and DNA damage.\[[@CIT9][@CIT10]\] Documented studies have shown that when folate is added back to these folate-deficient cells, there is a reversal of the S phase accumulation, and proliferation is restored.\[[@CIT9][@CIT10]\]

In human beings, folate deficiency has been shown to reduce the proportion of circulating T lymphocytes and their proliferation in response to mitogen activation, which in turn decreases resistance to infections.\[[@CIT11]\] There is also the association of folate deficiency with faster disease progression after infection of T lymphocytes by HIV type 1.\[[@CIT12][@CIT13]\] Risk of acute lymphocytic leukemia is said to increase with low folate status.\[[@CIT14][@CIT15]\]

Anemia in HIV-infected individuals occur in 10 to 20% at presentation and are diagnosed in 70 to 80% of patients over the course of the disease,\[[@CIT16][@CIT17]\] thus making it more common than thrombocytopenia or leukopenia in patients with AIDS. The etiology of anemia in HIV infection remains largely unclear. In recent years, several attempts have been made to elucidate the mechanisms leading to HIV-associated anemia. Direct infection of erythroid progenitors have been discussed,\[[@CIT18]\] but has not been proven. Furthermore, soluble factors like HIV proteins and cytokines have been suggested to inhibit growth of hematopoietic cells in the bone marrow of HIV-infected patients. So far, no emphatic statement could be made whether these factors are directly involved in myelosuppression or mediate their effect by inhibiting growth factor synthesis.\[[@CIT18]\] Other implicated factors include changes in cytokine production with subsequent effects on hematopoiesis;\[[@CIT19]\] opportunistic infectious agents such as *Mycobacterium avium* complex and parvovirus B-19;\[[@CIT20][@CIT21]\] administration of therapeutic agents such as zidovudine,\[[@CIT22]\] ganciclovir,\[[@CIT23]\] and trimethoprim-sulfamethoxazole;\[[@CIT24]\] and myelophthisis caused by cancers such as lymphosarcoma.\[[@CIT23]\] However, in sub-Saharan Africa where a good proportion of the populace are undernourished, nutritional anemias have become a major source of concern in the investigation of anemia in this group of patients and has thus formed the focus of this study. Most of the studies on anemia in HIV infection have been focused on iron studies, with less emphasis on folate and vitamin B12 levels. Folate is rapidly depleted in diseases, especially when there is prolonged anorexia, increased metabolic rate, and high cell turnover.\[[@CIT25]\] The HIV virus is known to have a rapid turnover and can generate up to 10 billion viron in 24 hours,\[[@CIT26]\] and the implication for this is a rapid depletion of folate stores. Plasma folate level ranges from 3 to 15 *μ*g/l.\[[@CIT25]\] The human daily requirement approximates to 50 *μ*g daily in infancy, to about 100 *μ*g daily in adults.\[[@CIT25]\] The actual amount is determined by metabolic and cell turnover rate. The total body folic acid stores are 5 to 10 ml with a half-life of about 0.7 hours.\[[@CIT1][@CIT25]\] It is widely and rapidly distributed throughout the body. Large amount is stored in the liver as methylated folic acid (34%), while about 66% is bound to plasma proteins.\[[@CIT1][@CIT27]\] 20 to 90% of ingested folic acid is excreted as folinic acid in the urine within 24 hours.\[[@CIT1][@CIT27]\]

Anemia has been associated with progression to AIDS and shorter survival time for HIV-infected patients.\[[@CIT28]\] Few studies have shown that if anemia had developed, recovery from it may be associated with improved survival.\[[@CIT29]\] Understanding the association between anemia and survival is important because treatments for anemia are available.

MATERIALS AND METHODS {#sec1-2}
=====================

One hundred HIV-positive patients, who attended the out-patient Clinic of the Lagos University Teaching Hospital, Idi-Araba, between the month of September and December, 2008, were recruited by systematic random sampling at the point of registration after obtaining verbal consent from the patients and ethical approval from the hospital ethical committee. Lagos is a southwestern state of Nigeria, noted for its multiethnic characteristics, and one of the few HIV treatment centers in Nigeria, supported by the Aids Prevention Initiative in Nigeria, a nongovernmental organization. The participants included were those confirmed positive for HIV infection by Enzyme-linked immunosorbent assay (ELISA) technique, antiretroviral naïve, within World Health Organization stage II, and with no clinical evidence of metabolic or systemic disorders. One hundred (100) HIV-negative participants were recruited by systematic random sampling from the blood donor clinic, having passed the donor criteria with a minimum hemoglobin (Hb) concentration of 12.5 g/dl.

0.5 ml of the plasma from each anticoagulated venous blood from both the patients and the control subjects were deproteinized with 1 ml of acetonitrite and centrifuged at a speed of 3 000 rpm to obtain a clear supernatant, which were subsequently injected into the High-performance liquid chromatography (HPLC) machine (by AGILENT, model 1100 series, Germany) for analyte separation and detection. Hematological investigations were done with the Sysmex automated cell counter to obtain the values of white blood cell count, Hb concentration, platelet count, and mean cell volume (MCV). CD4 cell count and viral load estimations were obtained by flow cytometry and RNA-Polymerase chain reaction, respectively. Quality control samples were run with each batch of test.

RESULTS {#sec1-3}
=======

As enumerated in [Table 1](#T0001){ref-type="table"}, the mean ages of participants in the HIV study group and control were 38 ± 2.3 and 32 ± 1.7 years, respectively. Mean plasma folate levels for study group and control group were 5.04 ± 1.2 and 15.89 ± 1.8 g/l, respectively (*P* = 0.0002). Mean Hb concentration for the HIV-positive participants were 9.5 ± 2.1 g/dl compared with a mean value of 13.0 ± 1.6 g/dl in the control group (*P* = 0.002). The MCV of the study group at 85 ± 3.8 fl was significantly higher than that for the control group with mean value of 80 ± 2.9 fl (*P* = 0.04).

###### 

Demographic profile with mean folate and mean hemoglobin levels

  Cases           Mean age (years)   Mean folate level (μg/l)   Mean Hemoglobin level (μg/l)                  
  --------------- ------------------ -------------------------- ------------------------------ ------- ------ ------
  Male            39                 32                         5.05                           15.93   3.92   13.5
  Female          36                 25                         4.9                            14.2    9.86   12.5
  Combined mean   38                 32                         5.04                           15.89   9.5    13.0

In [Table 2](#T0002){ref-type="table"}, low plasma folate levels (\<3.0 *μ*g/l) were demonstrated in 48% of all the HIV-positive subjects and in 52.8% of HIV-positive subjects with Hb concentration below 10 g/dl. Plasma folate levels correlated positively with CD4 cell count (r = 0.304, *P*\<0.05) and inversely with the viral load count (r = −0.566; *P*\<0.05) in HIV-positive participants.

###### 

Relating plasma folate levels to other hematological parameters in HIV positive subjects

  Parameters                           Folate values μg/ml (%)   X^2^                          *P* value   
  ------------------------------------ ------------------------- ----------------------------- ----------- ---------------------------
  Hemoglobin (Hb) concentration g/dl                                                                       
  \<10                                 38 (52.8)                 34 (47.2)                     2.35        0.125
  \>10                                 10 (35.7)                 18 (64.3)                                 
  White blood cell (WBC) count                                                                             
  \<2 500                              0 (0)                     2 (100)                                   0.267
  \>2 500                              48 (49)                   50 (51) (Fisher exact test)               
  Platelet (×10^9^)                                                                                        
  \<100                                0 (00)                    6 (100)                                   0.027 (Fisher exact test)
  \>100                                48(51.5)                  46(48.9)                                  
  CD4 cell count (cells/μl)                                                                                
  \<200                                20 (58)                   14 (42)                       2.95        0.08
  \>200                                26 (40)                   38 (60)                                   
  Viral load (RNA copies/ml)                                                                               
  \<50 000                             22 (42)                   30 (58)                       4.08        0.04
  \>50 000                             30 (62.5)                 18 (37.5)                                 

DISCUSSION {#sec1-4}
==========

Many studies around the world have documented persistently high occurrence of anemia in HIV-infected persons, especially as disease progresses;\[[@CIT16][@CIT17]\] these have been variously linked to poor dietary intake, effect of chronic inflammation, and opportunistic infections.\[[@CIT20][@CIT21]\] However, a large percentage of asymptomatic HIV-infected persons have shown early occurrence of anemia even in the absence of attributable etiological factors.\[[@CIT16]\] Friis *et al*., in a study of HIV-positive asymptomatic subjects in Southern Brazil, reported a plasma folate deficiency in 41% of the subjects studied.\[[@CIT30]\] This study postulates that the rapid viral replication characteristic of early phase of viral infection and consequent viral burden is capable of significant reduction in folate concentration and likelihood of anemia in the asymptomatic stages of HIV infection. This could explain the significant difference in the mean values of plasma folate level of 15.89 ± 1.8 *μ*g/l among control subjects and 5.04 ± 1.2 *μ*g/l in the study population (*P* = 0.0002). This position is supported by Friis *et al*.,\[[@CIT30]\] who in a study of 1 669 subjects in Zimbabwe, recorded a significantly lower plasma folate levels among the HIV-positive study group. Therefore, HIV could be said to be a negative predictor of plasma folate probably resulting from reduced intake, impaired absorption, or increased catabolism, or a combination of these factors. The Spearman's correlation coefficient among the study population indicated that the viral load significantly varies inversely with the plasma folate level in subjects studied (r = 0.566; *P*\<0.05).

The study showed a significant association between low plasma folate levels (\<3 *μ*g/l) and falling values of CD4 cell count of the subjects studied; 69.7% of these subjects with plasma folate level below 3 *μ*g/l had CD4 cell counts below 200 cells/*μ*l (*P* = 0.0004; OR, 2.92). These findings are in tandem with reports by Courtemanche *et al*.\[[@CIT31]\] who described higher CD4 apoptosis in moderate level of folate deficiency. The study also reported DNA damage and maturation arrest in the S-phase of the cell cycle which was reversible on folate repletion. Folate status is known to modulate immunocompetence and resistance to infections, and to affect cell-mediated immunity by reducing circulating T-lymphocytes and decreasing response to mitogen activation.\[[@CIT11]\] Therefore, a combination of these mechanism in a folate deficient immunocompromised host could result in a rapid deterioration, and faster progression to AIDS. The occurrence of anemia, as shown in [Table 2](#T0002){ref-type="table"} (Hb concentration below 10 g/dl), was demonstrated in about 52.8% of the HIV-positive population studied (*P* = 0.03); Castro *et al*.,\[[@CIT32]\] in a study of HIV-infected asymptomatic subjects in Southern Brazil, reported a prevalence of 41%. However, other studies have found no changes or even higher plasma folate levels in HIV-infected persons; these could strengthen earlier position that anemia in HIV-positive subjects is multifactorial.

CONCLUSION {#sec1-5}
==========

We may, from our findings, conclude that folate deficiency occurs as an early event in HIV infection, and that the introduction of folate prophylaxis may be justified as soon as HIV diagnosis is confirmed to delay disease progression and early occurrence of anemia.
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